Seat Belt Buckle Anchor Bolt – Focus of Recall – 240,510 Ford Explorer & Lincoln Aviator SUVs Potentially Affected

Kehoe Law Firm, P.C. is notifying consumers that Ford Motor Company (“Ford”) is recalling certain 2020-2021 Ford Explorer and Lincoln Aviator vehicles.

The seat belt buckle anchor bolts at one or more seating positions may be improperly secured. Additionally, vehicles may have an improperly secured seat belt retractor anchor bolt and/or seat belt anchor bolt at the second-row center seating position, if equipped.

A loose seat belt or seat belt buckle may not properly restrain an occupant during a crash, increasing the risk of injury.

240,510 2020-2021 Ford Explorer and Lincoln Aviator SUVs Potentially Impacted by the Recall

216,563 Ford Explorer and 23,947 Lincoln Aviator SUVs are the subject of the recall. The recalled vehicles may have an improperly secured seatbelt buckle anchor bolt at one or more seating positions. Vehicles may also have an improperly secured seatbelt retractor anchor bolt and/or seatbelt anchor bolt at the second-row center seating position if equipped.

Ford is not aware of any reports of accident or injury related to this condition.

Remedy for Ford Explorer and Lincoln Aviator Vehicle Owners and Lessees Affected by the Recall

Dealers will inspect seat belt buckle anchor bolts in all seating positions. Additionally, dealers will inspect the seat belt retractor anchor bolt and seat belt anchor bolt at the second-row center seating position, if equipped. If loose anchor bolts are found, the affected seat components will be replaced. Repairs will be performed free of charge.

Additional Information About the Vehicle Recall 

More information about the recall can be obtained by clicking the following:

NHTSA’s Safety Recall Report – 25V-093

NHTSA Recall Acknowledgement

Manufacturer Notice to Dealers

How Do I Know if My Vehicle Has Been Recalled?

To determine if your vehicle is subject to the recall, please click Check for Recalls to search vehicles, car seats, tires and other equipment for safety recalls, investigations, complaints and manufacturer communication.

Questions or Concerns About A Vehicle Defect or Safety Recall?

Vehicle owners and lessess affected by automotive defects or safety recalls are encouraged to contact Kehoe Law Firm, P.C. by sending us a message below or contacting Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation evaluation of potential legal claims.

Our class action legal services are on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

About Kehoe Law Firm, P.C. 

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and corporate misconduct. Our attorneys have served as Lead or Co-Lead Counsel in cases recovering over $10 billion on behalf of institutional and individual investors and consumers.

Through class action litigation, we hold corporations accountable for securities fraud, breaches of fiduciary duty, unfair or inadequate mergers and acquisitions, and antitrust violations. We also represent whistleblowers and prosecute data breach, consumer protection, and employment law violations, as well as cases involving retirement plan mismanagement and deceptive business practices. With a results-driven approach, we pursue impactful litigation to achieve meaningful results and recoveries for those we represent.

bluebird bio – BLUE

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of bluebird bio, Inc. (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by “funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (‘SK Capital’) in collaboration with a team of highly experienced biotech executives.”

On February 21, 2025, bluebird bio announced an agreement to be acquired in a deal bluebird bio said is a “transaction [that] is the only viable solution to generate value for stockholders.”

On this news, bluebird bio’s stock was down more than 38% pre-market on February 21, 2025.  

Obtain More Information About the Securities Investigation 

bluebird bio investors are encouraged to can send us a message or complete Kehoe Law Firm’s Stockholder Information Request form to contact an attorney for a free, no-obligation legal evaluation.

For direct inquiries, bluebird bio shareholders should contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected].

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Cardlytics, Inc. – CDLX

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Cardlytics, Inc. (“Cardlytics” or the “Company”) (NASDAQ:CDLX) who purchased or otherwise acquired Cardlytics stock shares between March 14, 2024 and August 7, 2024, inclusive (the “Class Period”).

Cardlytics investors who acquired their stock during the Class Period with losses greater than $50,000 are encouraged to send us a message or complete our Kehoe Law Firm’s Stockholder Information Request form to reach an attorney for a free, no-obligation evaluation of potential legal claims.

Cardlytics Securities Fraud Class Action Lawsuit Allegations

A securities class action lawsuit has been filed against Cardlytics, alleging violations of federal securities laws. The complaint alleges that throughout the Class Period, the Cardlytics defendants failed to disclose material adverse facts to investors, including that increased consumer engagement led to an increase in consumer incentives; the Company was unable to increase billings in line with increased consumer engagement; and, as a result, there was a significant risk of slowing or declining revenue growth; and changes to its Ads Decision Engine (“ADE”) contributed to the “under-delivery” of budgets and customer billing estimates.

Cardlytics Investors: Learn More About Your Legal Rights

Investors with significant losses who acquired Cardlytics stock during the Class Period can contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the securities investigation and receive a free, no-obligation legal evaluation.

Investors have until March 25, 2025 to petition the Court for appointment as lead plaintiff. The Court typically appoints the investor with the largest financial interest who also meets the adequacy and typicality requirements. Shareholders who wish to discuss the lead plaintiff process should contact us.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

 

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Humacyte, Inc. – HUMA

Kehoe Law Firm, P.C. is investigating whether certain officers and directors of Humacyte, Inc. (“Humacyte”) (NASDAQ:HUMA) breached their fiduciary duties by failing to manage Humacyte in an acceptable manner and whether Humacyte and its shareholders were harmed as a result.

The investigation concerns whether certain officers and directors of Humacyte provided false and misleading information about its manufacturing facilities and clinical sites, including its Durham, North Carolina, facility, which—according to an FDA Form 483—disclosed multiple violations, such as inadequate quality oversight and a lack of microbial quality assurance and testing.

Humacyte Investors: Learn More About the Investigation and Your Legal Options

Humacyte investors who want to learn more about the breach of fiduciary duties investigation or discuss potential legal claims can send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation of potential legal claims.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

 

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

BioAge Labs, Inc. Securities Investigation – BIOA

Kehoe Law Firm, P.C. is investigating securities claims on behalf of investors of BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ:BIOA) who purchased BioAge stock pursuant or traceable to the registration statement for its initial public offering (“IPO”) which occurred on or about September 26, 2024.

BioAge investors who obtained their securities pursuant or traceable to the Company’s IPO are encouraged to send us a message or complete Kehoe Law Firm’s Stockholder Information Request form to discuss their rights with an attorney.

Class Action Lawsuit Filed Against BioAge

A class action lawsuit has been filed in federal court against BioAge alleging violations of federal securities laws on behalf of investors who acquired BioAge stock in connection with the Company’s September 2024 IPO.

On or about September 26, 2024, BioAge, “a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases,” conducted its IPO, selling 12,650,000 shares of common stock at $18.00 per share.

On December 6, 2024, BioAge announced the discontinuation of its STRIDES Phase 2 study of azelaprag. The company stated, among other things, that the emerging safety profile of the drug was inconsistent with its goal of a best-in-class oral obesity therapy.

Following this news, BioAge’s stock price plummeted $15.44 per share (76.85%), closing at $4.65 per share on December 9, 2024.

BioAge Shareholders: Learn More About the Securities Class Action and Your Legal Options

Investors who acquired their BioAge stock pursuant or traceable to the Company’s IPO can also contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to discuss the securities class action and receive a free, no-obligation legal evaluation.

Investors who purchased BioAge stock pursuant to the Company’s IPO have until March 10, 2025 to petition the Court for appointment as lead plaintiff. The Court typically appoints the investor with the largest financial interest who also meets the adequacy and typicality requirements. Investors who wish to discuss their rights or the lead plaintiff process are encouraged to contact our firm.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]